Literature DB >> 2841935

Erythropoietin receptor of a human leukemic cell line with erythroid characteristics.

K Hitomi1, K Fujita, R Sasaki, H Chiba, Y Okuno, S Ichiba, T Takahashi, H Imura.   

Abstract

A new cell line of human erythroleukemia cells differentiates spontaneously so that 30% of the cells are always hemoglobinized. Erythropoietin did not affect the percentage of such cells but stimulated the cell growth, indicating that the cells have functioning receptors. Binding of human recombinant radioiodinated erythropoietin to the receptors was specific. The bound ligand was internalized into cells at 37 degrees C but not at 15 degrees C. Scatchard analysis showed two classes of binding sites. Covalent binding of erythropoietin to its receptors yielded two products detected on sodium dodecyl sulfate-polyacrylamide gels electrophoresed under reducing conditions. Under non-reducing conditions, these species disappeared and larger products appeared.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841935     DOI: 10.1016/0006-291x(88)90225-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium.

Authors:  H Kimata; A Yoshida; C Ishioka; S Masuda; R Sasaki; H Mikawa
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 2.  Erythropoietin receptor. Subunit structure and activation.

Authors:  A D D'Andrea; L I Zon
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

3.  DNA replication of parvovirus B 19 in a human erythroid leukemia cell line (JK-1) in vitro.

Authors:  T Takahashi; K Ozawa; K Takahashi; Y Okuno; T Takahashi; Y Muto; F Takaku; S Asano
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 4.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.